03:46 AM EDT, 06/02/2025 (MT Newswires) -- Sanofi ( SNY ) has agreed to acquire Blueprint Medicines ( BPMC ) in a deal worth up to $9.5 billion, the companies said Monday.

Under the deal, Sanofi ( SNY ) will launch a tender offer to acquire all outstanding shares of Blueprint for $129 each in cash, plus a contingent value right that entitles the holder to receive potential development and regulatory milestone payments of $2 and $4 per right, the companies said.

Blueprint shares closed at $101.35 on Friday.

Through the deal, Sanofi ( SNY ) will acquire Ayvakit/Ayvakyt, an approved therapy in the US and the EU for advanced and indolent systemic mastocytosis, an immunology disease. The drug saw net revenue of $479 million in 2024, the companies said.

Sanofi ( SNY ) plans to fund the deal with cash on hand and new debt. The purchase is expected to close in Q3, subject to customary conditions.

Sanofi ( SNY ) expects the deal to be accretive to earnings after 2026.